Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study

BACKGROUND: Anti-angiogenic therapy is known to induce a greater degree of hypoxia, including in glioblastoma (GBM). Evofosfamide (Evo) is a hypoxia-activated prodrug which is reduced, leading to the release of the alkylating agent bromo-isophosphoramide mustard. We assessed the safety, tolerability...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Brenner, Andrew, Zuniga, Richard, Sun, Jessica D, Floyd, John, Hart, Charles P, Kroll, Stew, Fichtel, Lisa, Cavazos, David, Caflisch, Laura, Gruslova, Aleksandra, Huang, Shiliang, Liu, Yichu, Lodi, Alessia, Tiziani, Stefano
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2018
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6071657/
https://ncbi.nlm.nih.gov/pubmed/29415215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy015
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi